User menu

The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)

Bibliographic reference Bruyere, O. ; Devogelaer, Jean-Pierre ; Kanis, J. A. ; Ibar-Abadie, M.-E. ; Alsayed, N. ; et. al. The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). In: Osteoporosis International : with other metabolic bone diseases, Vol. 21, no. 5, p. 713-722 (2010)
Permanent URL http://hdl.handle.net/2078.1/34420
  1. Walsh K, Sandars J (2008) Competing interests and research in medical education. Postgrad Med J 84:113–114
  2. Haines IE, Olver IN (2008) Are self-regulation and declaration of conflict of interest still the benchmark for relationships between physicians and industry? Med J Aust 189:263–266
  3. Shaldon S (2008) Conflict of interest in clinical guidelines should be avoided. Nephrol Dial Transplant 23:1771, author reply 1772
  4. Elliott Kevin, Scientific Judgment and the Limits of Conflict-of-Interest Policies, 10.1080/08989620701783725
  5. Sismondo S (2008) How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Soc Sci Med 66:1909–1914
  6. Doucet M, Sismondo S (2008) Evaluating solutions to sponsorship bias. J Med Ethics 34:627–630
  7. Chabner BA (2008) Conflict of interest: in the eye of the beholder? Oncologist 13:212–213
  8. Camilleri M, Cortese DA (2007) Managing conflict of interest in clinical practice. Mayo Clin Proc 82:607–614
  9. Tungaraza T, Poole R (2007) Influence of drug company authorship and sponsorship on drug trial outcomes. Br J Psychiatry 191:82–83
  10. Duvall DG (2006) Conflict of interest or ideological divide: the need for ongoing collaboration between physicians and industry. Curr Med Res Opin 22:1807–1812
  11. Weinfurt KP, Friedman JY, Dinan MA, Allsbrook JS, Hall MA, Dhillon JK, Sugarman J (2006) Disclosing conflicts of interest in clinical research: views of institutional review boards, conflict of interest committees, and investigators. J Law Med Ethics 34(581–591):481
  12. Bekelman JE, Li Y, Gross CP (2003) Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289:454–465
  13. Shaywitz D, Stossel T (2009) It’s time to fight the “PharmaScolds”. In Wall Street Journal
  14. Collier J (2009) Doctors, patients, and the pharmaceutical industry. BMJ 338:b443
  15. Royal-College-of-Physicians (2009) Innovating for health: patient, physicians, the pharmaceutical industry and the NHS. Report of a Working Party, London
  16. Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH Jr, Thomson GE, Wofsy D (2009) Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA 301:1367–1372
  17. Christensen JA, Orlowski JP (2005) Bounty-hunting and finder’s fees. IRB 27:16–19
  18. Moses H 3rd, Dorsey ER, Matheson DH, Thier SO (2005) Financial anatomy of biomedical research. JAMA 294:1333–1342
  19. Olesen J, Lekander I, Andlin-Sobocki P, Jonsson B (2007) Funding of headache research in Europe. Cephalalgia 27:995–999
  20. Philipson L (2005) Medical research activities, funding, and creativity in Europe: comparison with research in the United States. JAMA 294:1394–1398
  21. Demotes-Mainard J, Canet E, Segard L (2006) Public–private partnership models in France and in Europe. Therapie 61(325–334):313–323
  22. Moses H 3rd, Braunwald E, Martin JB, Thier SO (2002) Collaborating with industry—choices for the academic medical center. N Engl J Med 347:1371–1375
  23. Bero LA, Glantz S, Hong MK (2005) The limits of competing interest disclosures. Tob Control 14:118–126
  24. Sismondo S (2008) Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials 29:109–113
  25. Niebyl JR (2008) The pharmaceutical industry: friend or foe? Am J Obstet Gynecol 198:435–439
  26. Haas J (2008) Commentary: epidemiology and the pharmaceutical industry: an inside perspective. Int J Epidemiol 37:53–55, discussion 65-58
  27. Boyd EA, Bero LA (2007) Defining financial conflicts and managing research relationships: an analysis of university conflict of interest committee decisions. Sci Eng Ethics 13:415–435
  28. Sismondo S (2007) Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med 4:e286
  29. Reginster JY (2007) The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 56:2105–2110
  30. Pharmaceutical Research and Manufacturers of America (PhRMA) (2008) Code on interactions with healthcare professionals
  31. Wager E, Field EA, Grossman L (2003) Good publication practice for pharmaceutical companies. Curr Med Res Opin 19:149–154
  32. Schulman KA, Seils DM, Timbie JW, Sugarman J, Dame LA, Weinfurt KP, Mark DB, Califf RM (2002) A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med 347:1335–1341
  33. Campbell P (2001) Declaration of financial interests. Nature 412:751
  34. Wager E (2004) The need for trial identifiers. Curr Med Res Opin 20:203–206
  35. Hirsch L (2008) Trial registration and results disclosure: impact of US legislation on sponsors, investigators, and medical journal editors. Curr Med Res Opin 24:1683–1689
  36. Goldhahn J, Mitlak B, Aspenberg P, Kanis JA, Rizzoli R, Reginster JY (2008) Critical issues in translational and clinical research for the study of new technologies to enhance bone repair. J Bone Jt Surg Am 90(Suppl 1):43–47
  37. Compston J, Reid DM, Boisdron J, Brandi ML, Burlet N, Cahall D, Delmas PD, Dere W, Devogelaer JP, Fitzpatrick LA, Flamion B, Goel N, Korte S, Laslop A, Mitlak B, Ormarsdottir S, Ringe J, Rizzoli R, Tsouderos Y, Van Staa T, Reginster JY (2008) Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int 19:1247–1250
  38. Lekkerkerker F, Kanis JA, Alsayed N, Bouvenot G, Burlet N, Cahall D, Chines A, Delmas P, Dreiser RL, Ethgen D, Hughes N, Kaufman JM, Korte S, Kreutz G, Laslop A, Mitlak B, Rabenda V, Rizzoli R, Santora A, Schimmer R, Tsouderos Y, Viethel P, Reginster JY (2007) Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 18:1311–1317
  39. Reginster JY, Abadie E, Delmas P, Rizzoli R, Dere W, der Auwera P, Avouac B, Brandi ML, Daifotis A, Diez-Perez A, Calvo G, Johnell O, Kaufman JM, Kreutz G, Laslop A, Lekkerkerker F, Mitlak B, Nilsson P, Orloff J, Smillie M, Taylor A, Tsouderos Y, Ethgen D, Flamion B (2006) Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporos Int 17:1–7
  40. Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, Bruyere O, Calvo G, Devogelaer JP, Dreiser RL, Herrero-Beaumont G, Kahan A, Kreutz G, Laslop A, Lemmel EM, Nuki G, Van De Putte L, Vanhaelst L, Reginster JY (2004) Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage 12:263–268
  41. Holgate ST, Bousquet J, Chung KF, Bisgaard H, Pauwels R, Fabbri L, Rabe K, Doherty M, Snell NJ, Cuss F, D’Amato M, Reginster JY (2004) Summary of recommendations for the design of clinical trials and the registration of drugs used in the treatment of asthma. Respir Med 98:479–487
  42. Delmas PD, Calvo G, Boers M, Abadie E, Avouac B, Kahan A, Kaufman JM, Laslop A, Lekkerkerker JF, Nilsson P, Van Zwieten-Boot B, Kreutz G, Reginster JY (2002) The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporos Int 13:1–5
  43. Vignon E, Garnero P, Delmas P, Avouac B, Bettica P, Boers M, Ehrich E, MacKillop N, Rovati L, Serni U, Spector T, Reginster JY (2001) Recommendations for the registration of drugs used in the treatment of osteoarthritis: an update on biochemical markers. Osteoarthritis Cartilage 9:289–293
  44. Group for the Respect of Ethics and Excellence in Science (GREES) (1998) Recommendations for the registration of drugs used in the treatment of rheumatoid arthritis: rheumatoid arthritis section. Br J Rheumatol 37:211–215
  45. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, Fujiwara S, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155–162
  46. Gene-Badia J., Labour's health policy is having paradoxical effect in Iberian countries, 10.1136/bmj.318.7181.466
  47. The PLoS Medicine Editors (2008) Making sense of non-financial competing interests. PLoS Med 5:e199
  48. Bero L (2008) “Experimental” institutional models for corporate funding of academic research: unknown effects on the research enterprise. J Clin Epidemiol 61:629–633
  49. de Haas ER, de Vijlder HC, van Reesema WS, van Everdingen JJ, Neumann HA (2007) Quality of clinical practice guidelines in dermatological oncology. J Eur Acad Dermatol Venereol 21:1193–1198
  50. Reed DA, Cook DA, Beckman TJ, Levine RB, Kern DE, Wright SM (2007) Association between funding and quality of published medical education research. JAMA 298:1002–1009
  51. Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326:1167–1170
  52. Angell M, Kassirer JP (1996) Editorials and conflicts of interest. N Engl J Med 335:1055–1056
  53. Drazen JM, Curfman GD (2002) Financial associations of authors. N Engl J Med 346:1901–1902
  54. Ancker JS, Flanagin A (2007) A comparison of conflict of interest policies at peer-reviewed journals in different scientific disciplines. Sci Eng Ethics 13:147–157
  55. Chaudhry S, Schroter S, Smith R, Morris J (2002) Does declaration of competing interests affect readers’ perceptions? A randomised trial. BMJ 325:1391–1392
  56. Healy D, Cattell D (2003) Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry 183:22–27
  57. McLennan M, Leong FC, Steele A, Harris J (2008) The influence of industry sponsorship on the acceptance of abstracts and their publication. Am J Obstet Gynecol 198(579):e571–e574
  58. Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R, Kotzin S, Nicholls MG, Nylenna M, Overbeke AJ, Sox HC, Van Der Weyden MB, Wilkes MS (2001) Sponsorship, authorship, and accountability. Lancet 358:854–856
  59. Bodenheimer T (2000) Uneasy alliance—clinical investigators and the pharmaceutical industry. N Engl J Med 342:1539–1544
  60. International Committee of Medical Journal Editors (1997) Uniform requirements for manuscripts submitted to biomedical journals. JAMA 277:927–934
  61. Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM, Field EA, Gurr JA, Marx ME, Patel M, Sanes-Miller C, Yarker YE (2009) Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ 339:b4330
  62. Jacobs A, Wager E (2005) European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. Curr Med Res Opin 21:317–322
  63. Norris R, Bowman A, Fagan JM, Gallagher ER, Geraci AB, Gertel A, Hirsch L, Ross PD, Stossel TP, Veitch K, Woods D (2007) International Society for Medical Publication Professionals (ISMPP) position statement: the role of the professional medical writer. Curr Med Res Opin 23:1837–1840
  64. Moher D, Schulz KF, Altman D (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285:1987–1991